Company profilePharmaceutical#59 of 1,318 in Pakistan1 DRAP alert

GEOFMAN PHARMACEUTICALS

Pharmaceutical company · 223 brands · 224 molecules

Ranked #3 of 11 companies in Solutions Affecting The Electrolyte Balance

223 registered products 66 pharmaceutical brands 224 distinct molecules 1 DRAP alert

Company overview

223
registered products
66
pharmaceutical brands
224
distinct molecules
12
therapeutic classes
1
DRAP alerts

GEOFMAN PHARMACEUTICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 223 product registrations across 224 distinct molecules. It is the 59th largest registrant in Pakistan by product count, and ranks 3rd of 11 in Solutions Affecting The Electrolyte Balance. Its portfolio is concentrated in Solutions Affecting The Electrolyte Balance and Blood Glucose Lowering Drugs, Excluding Insulin. DRAP has issued 1 alert involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by GEOFMAN

97 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

91
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
20252
202689

Top molecules by brand count

Neomycin6 brands
Artemether5 brands
Thiamine5 brands
Amoxicillin4 brands
Nicotinamide4 brands
Pyridoxine4 brands

Therapeutic classes

Solutions Affecting The Electrolyte Balance · 8Blood Glucose Lowering Drugs, Excluding Insulin · 4Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 4Macrolides, Lincosamides And Streptogramins · 3Calcium Channel Blockers · 3Nasal Preparations · 2Corticosteroid Combinations, Topical · 2Beta-Lactam Antibacterials, Penicillins · 2Vitamin B Complex Plain & With Vitamin C · 2Antimycobacterials (Antituberculosis) · 2Lipid Modifying Agents · 2Tetracyclines · 1

Conditions treated

Eczema/Psoriasis/Dermatitis · 1Contraceptives · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official145 products · Rs 10.72 – Rs 3,531.46
DVAGO3 products · Rs 19.44 – Rs 1,472.5
Servaid2 products · Rs 47.44 – Rs 687
Median across source: Rs 367.22

Regulatory record

1 alert in the DRAP feed we track.

Recall Alert: Drug Product; Micogen-B Cream (Batch#MB-012/22) by M/s. Delux Chemical Indus
2023-04-05

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD. holds 123 molecules not in this portfolio
AlbuterolAminophyllineAmlodipineAmlodipine BaseAmmonium ChlorideAmmonium Chloride Containing Expectorants
Wilshire Laboratories (Private) Limited holds 109 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmlodipineAmoxycillin BaseAnastrozole
NEUTRO PHARMA (PVT) LTD. holds 103 molecules not in this portfolio
AcetylcysteineAcyclovirAlbendazoleAnastrazoleAnastrozoleAntimony

Get the full profile for GEOFMAN

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.